Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Significance of MRD in CLL

Tanya Siddiqi • 28 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Venetoclax
CLL14

Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, explores the use of minimal residual disease (MRD) testing in the clinic for chronic lymphocytic leukemia (CLL) patients, and its use in determining the endpoint for treatment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Tanya Siddiqi

Expanding the CAR platform for NHL 11:30
Expanding the CAR platform for NHL
Catherine Bollard et al. • 28 Sep 2025
CAR-T in CLL: updates from the TRANSCEND-CLL-004 trial and when to choose CAR-T for these patients 2:19
CAR-T in CLL: updates from the TRANSCEND-CLL-004 trial and when to choose CAR-T for these patients
Tanya Siddiqi • 7 Feb 2025
Future directions for CAR-T therapy in CLL: the potential of combining CAR T-cells with other agents 1:29
Future directions for CAR-T therapy in CLL: the potential of combining CAR T-cells with other agents
Tanya Siddiqi • 7 Feb 2025
Why has CAR-T been more challenging to manufacture for CLL? 1:00
Why has CAR-T been more challenging to manufacture for CLL?
Tanya Siddiqi • 7 Feb 2025

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals